Japan · Delayed Price · Currency is JPY Ajinomoto Co. Earnings Call Transcripts
Fiscal Year 2026
-
Record sales and business profit were achieved in FY 2025, with strong growth in Healthcare, functional materials, and food products. FY 2026 guidance targets further record highs, while risks from Middle East instability are being managed through flexible cost and supply strategies.
-
Governance and compliance frameworks were strengthened, with a revised code of conduct and new compliance committee. Executive compensation is being restructured to better align with performance and shareholder value, while portfolio and audit practices emphasize transparency and risk management.
-
Sustainability is central to strategy, with a focus on agri-food system transformation, health, and nutrition. Key innovations like biostimulants and AjiPro-L target both environmental and business growth, supported by partnerships and financial schemes. Sales targets for these solutions are set to double by 2030.
-
Record highs in sales and profit were achieved in Q3 FY2025, driven by strong growth in Seasonings, Foods, and Functional Materials. Upward revisions were made to full-year profit forecasts, with robust performance expected to continue, supported by asset sales and margin improvements.
-
First half FY2025 results were flat year-over-year, with profit growth in healthcare and others offset by declines in frozen foods and umami seasonings. Management expects a strong recovery in the second half, supported by strategic actions, new technologies, and continued investment in innovation.
-
Organic sales grew 3% year-on-year, with business profit up 12% and profit margin at 13%. Strong gains in Functional Materials and Bio-Pharma offset challenges in Japan's frozen foods, while currency and raw material costs remain key risks.
Fiscal Year 2025
-
Latin American operations are expanding with strong market shares, robust distribution, and new product launches in food and bio-fine chemicals. Sustainability initiatives like the Biocycle and Agipro L are central, with a focus on GHG reduction and digital transformation. Growth is supported by innovation, human capital, and adaptation to evolving consumer needs.
-
Plans to double medical food sales by FY2030 focus on innovation, global expansion, and leveraging amino science. Cambrooke and Nualtra drive growth through strong patient and practitioner relationships, rapid product development, and high-margin segments, outpacing market growth.
-
Record FY2024 sales and business profit were achieved, despite one-time costs from structural reforms. FY2025 is forecasted to deliver further growth, with strong performance expected in seasonings, foods, and functional materials, and a major share buyback announced.
-
A rapid CEO transition was enabled by robust succession planning, with the new president expected to accelerate the 2030 roadmap. The board is evolving its strategic focus, enhancing executive compensation and audit practices, and addressing capital efficiency and corporate culture transformation.
-
Record revenue and profit were achieved for the first three quarters, driven by strong overseas and healthcare segments, while domestic food and coffee businesses faced margin pressure from rising raw material costs. Ongoing product innovation and market expansion support future growth.
-
Record interim sales and profit were achieved, with upward revisions to full-year forecasts, driven by strong overseas and functional materials performance. Domestic coffee and frozen foods faced margin pressure from rising costs, but strategic shifts and product innovation are underway. Shareholder returns were enhanced with a stock split and major buyback.
-
Record Q1 revenue and business profit were achieved, driven by strong overseas growth in seasonings, frozen foods, and functional materials. Strategic investments and price hikes are expected to support further profit recovery, with CDMO and Forge showing strong order momentum.